OptimizeRx Corp
For the period ended Jun 9, 2026. Filed Apr 30, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 9, 2026 · Filed Apr 30, 2026
Contents
APPENDIX A
NON-GAAP FINANCIAL MEASURES
This proxy statement includes certain references to Adjusted EBITDA, which is a financial measure not derived in accordance with generally accepted accounting principles (GAAP). This non-GAAP financial measure is a measure of performance not defined by accounting principles generally accepted in the United States and should be considered in addition to, not in lieu of, GAAP reported measures. Additionally, this non-GAAP measure may not be comparable to similarly titled measures reported by other companies. However, management believes that presenting certain non-GAAP financial measures provides additional information to facilitate comparison of the Company’s historical operating results and trends in its underlying operating results and provides transparency on how the Company evaluates its business. Management uses this non-GAAP financial measure in making financial, operating and planning decisions and in evaluating the Company’s performance. Management believes that financial information excluding certain items that are not considered to reflect the Company’s ongoing operating results, such as the measure listed below, improves the comparability of year-to-year results. Consequently, management believes that investors may be able to better understand the Company’s operating results excluding these items. Non-GAAP financial measures may reflect adjustments for items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance, deferred income taxes, as well as other items that management believes are not related to the Company’s ongoing performance.
For the Twelve Months Ended December 31, 2025
($ in thousands)
| Net income | 5,132 |
|---|---|
| Depreciation and amortization | 4,327 |
| Stock-based compensation | 6,962 |
| Impairment charges | 368 |
| Severance charges | 275 |
| Shareholder activist related fees | 451 |
| CEO search fees | 225 |
| Other income | (198) |
| Interest expense (income), net | 4,941 |
| Income tax expense (benefit) | 1,818 |
| Adjusted EBITDA (as reported) | 24,301 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.